Rituximab in Rheumatoid Arthritis in patients who failed therapy with tumour necrosis factor-blockers: a multi-centre clinical observational real-life study (phase IIIb)
| ISRCTN | ISRCTN27093749 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN27093749 |
| Secondary identifying numbers | 3.1 |
- Submission date
- 01/09/2006
- Registration date
- 21/12/2006
- Last edited
- 21/12/2006
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Josef Smolen
Scientific
Scientific
Medical University of Vienna
Waehringer Guertel 18-20
Vienna
1090
Austria
| Phone | +43 (0) 1 40 400 4381 |
|---|---|
| josef.smolen@wienkav.at |
Study information
| Study design | A clinical observational real-life study investigating the effect of Rituximab |
|---|---|
| Primary study design | Observational |
| Secondary study design | Multi-centre |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study acronym | RIRA |
| Study objectives | To investigate the efficacy of treatment in real life (routine clinical care) with rituximab (MabThera®) in patients with active Rheumatoid Arthritis (RA) whose current treatment with a Tumour Necrosis Factor (TNF)-blocker (Etanercept - Enbrel®, Infliximab Remicade® or Adalumimab - Humira®) in combination with Methotrexate (MTX) is insufficient. |
| Ethics approval(s) | Ethical committee and internal review board of the Medical University of Vienna (reference Number 049/2006), date of approval: 14/03/2006. |
| Health condition(s) or problem(s) studied | Rheumatoid Arthritis (RA) |
| Intervention | Infusion with rituximab (MabThera®) |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II/III |
| Drug / device / biological / vaccine name(s) | Rituximab (MabThera®), Etanercept (Enbrel®), Infliximab (Remicade®), Adalumimab (Humira®) and Methotrexate (MTX) |
| Primary outcome measure | Primary outcome measure will be the frequency of reaching low disease activity or remission as measured by the Clinical Disease Activity Index (CDAI) (less than or equal to ten). |
| Secondary outcome measures | 1. Major CDAI response of -13.9 2. Moderate CDAI response of -6.7 3. Disease Activity Score based on 28 joints (DAS28) 4. Simplified Disease Activity Index (SDAI) 5. American College of Rheumatology (ACR) response criteria (20%, 50%, 70%) 6. Health Assessment Questionnaire (HAQ) 7. Short Form Health Sruvey (SF-36) |
| Overall study start date | 01/09/2006 |
| Completion date | 01/09/2007 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 20 |
| Key inclusion criteria | 1. Women or men 18 years of age or older 2. Diagnosis of RA according to the revised 1987 criteria of the American Rheumtololgy Association (ARA) for at least three months prior to first administration of study medication 3. The current treatment with Etanercept, Infliximab or Adalimumab in combination with MTX is insufficient. The patients disease is considered to be active despite Disease Modifying Anti-Rheumatic Drug (DMARD) treatment 4. Active disease at the time of screening as defined by: a. more than or equal to six swollen joints on a 66/68 joint count b. more than or equal to six tender joints on a 66/68 joint count c. and one out of the following three categories: i. Erythrocyte Sedimentation Rate (ESR) more than or equal to 28 mm/h ii. C-Reactive Protein (CRP) more than or equal to 1.5 mg/dl iii. Morning stiffness more than or equal to 45 minutes d. and one out of the following three categories: i. bone erosion by x-ray prior to first administration of study medication ii. Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibody-positive iii. Rheumatoid Factor (RF)-positive at screening 5. If using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other analgesics for RA, must be on a stable dose for at least two weeks prior to the first administration of study agent 6. If using oral corticosteroids, must be on a stable dose equivalent to less than or equal to 10 mg of prednisone/day for at least two weeks prior to first administration of study agent. If currently not using corticosteroids, the subject must not have received oral corticosteroids for at least two weeks prior to first administration of study medication 7. Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilisation) during the study and for six months after receiving the last administration of study agent 8. Female subjects of childbearing potential must test negative for pregnancy. A pregnancy test will be performed at the beginning and at the end of the study 9. The screening laboratory test must meet the following criteria: a. haemoglobin more than or equal to 8.5 g/dl providing the low haemoglobin level is not due to other diseases than anemia of chronic inflammation b. White Blood Cells (WBC) more than or equal to 3500/µl c. neutrophils more than or equal to 1500/µl d. platelets more than or equal to 100,000/µl e. serum transaminase less than or equal to two times the Upper Limit of Normal (ULN) f. serum creatinine less than or equal to 1.7 mg/dl 10. The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures |
| Key exclusion criteria | Patients are excluded if they meet one of the following criteria: 1. Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment 2. Patients with other inflammatory diseases that might interfere with the evaluation of the RA 3. Patients with fibromyalgia syndrome 4. Use of IntraMuscular (IM), IntraVenous (IV), IntraArterial (IA) corticosteroids within four weeks prior to screening 5. Treatment with any investigational drug within three months prior to screening 6. A history of known allergy to murine proteins, e.g. allergy to Infliximab 7. History of infected joint prothesis within the previous five years 8. Chronic infections 9. History of active tuberculosis requiring treatment within the previous three years, or history of opportunistic infections within two months, uncontrolled active infection or documented Human Immunodeficiency Virus (HIV) infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis (TB) without documented adequate therapy if they will not be treated according to the local TB guidelines 10. Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk 11. History of lymphoproliferative disease, any current malignancies or history of malignancy within five years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin 12. History of drug abuse |
| Date of first enrolment | 01/09/2006 |
| Date of final enrolment | 01/09/2007 |
Locations
Countries of recruitment
- Austria
Study participating centre
Medical University of Vienna
Vienna
1090
Austria
1090
Austria
Sponsor information
Medical University of Vienna (Austria)
University/education
University/education
c/o Prof. Dr. Josef Smolen
Waehringer Guertel 18-20
Vienna
1090
Austria
| Phone | +43 (0) 1 40 400 4381 |
|---|---|
| josef.smolen@wienkav.at | |
| Website | http://www.meduniwien.ac.at/ |
"ROR" |
https://ror.org/05n3x4p02 |
Funders
Funder type
Other
The trial is an investigator driven study without any grant support, Roche provides the medication.
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
